Trending Topic

4 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Bruton tyrosine kinase (BTK) plays a functional and integral role in B-cell receptor (BCR) signalling and is expressed in normal and malignant B cells. Given BTK’s central role in the survival and proliferation of malignant B cells, BTK inhibitors have been developed for use in various B-cell malignancies, with several US Food and Drug Administration approvals in […]

Corey Cutler, ASH 2019: Evolving Treatment for Patients with GvHD

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Dec 18th 2019

At the 61st ASH Annual Meeting & Exposition, Corey Cutler, Dana Farber Cancer Institute, discusses his presentation: The Evolving Treatment Landscape for Patients with GvHD: More Options, More Decisions, Better Outcomes!

Questions

1. What are the major challenges in the treatment of patients with graft-versus-host disease (GvHD)? (0:05)

2. How have recent advances in understanding of the biology of GvHD impacted on patient management? (0:45)

3. What do you consider the most important emerging therapies for GvHD? (1:22)

4. What do healthcare professionals need to know in terms of monitoring and appropriate management of treatment-related adverse events? (1:54)

5. What other key messages of this symposium would you like to highlight? (2:33)

 

Corey Cutler has no conflicts of interest to declare in relation to this video.

Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.

 

 

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup